Development and manufacturing machine specialists, groninger, have opened a new showroom at its headquarters based in Crailsheim, Germany.
Development and manufacturing machine specialists, groninger, have announced, in a July 16, 2019 press release, the opening of a new showroom at its headquarters based in Crailsheim, Germany.
Comprising 150 square meters, the showroom offers a separate area where groninger customers can view new machines and technologies, and also where they can have one-to-one conversations with company representatives.
“Our intention is to not only provide a separate area for our customers, but also keep them informed about our newest machines, innovations, and technological advancements all year round,” said Dirk Schuster, sales director and member of the management board of groninger. “That’s why we decided to set up a showroom and training center on the company premises in Crailsheim. The showroom is located right next to groninger’s large assembly halls.”
The company builds customized machines for use in the filling and closing of pharmaceutical products and as a result customer requests can be specific in nature. Additionally, as a result of the changing regulatory landscape, particularly in the sterile pharmaceutical industry, the company states that it is witnessing an increased demand for more complex machines and hence, customer consultations are of vital importance.
“As we also want to have satisfied customers in the future, we take our time for a quality consultation, of course,” added Schuster. “The time at exhibitions where you traditionally meet a lot of customers is usually too short for an informative discussion. Taking the time to discuss project details, demonstrate examples, or identify various solutions is hard to do in such a limited time frame-for both our customers and us.”
Source: groninger
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.